Is sepsis a pro-resolution deficiency disorder?

Medical Hypotheses

Volumn 80, Issue 3, 2013, Pages 297-299

  Das, Undurti N ^a,b  

^a UND LIFE SCIENCES   (United States)

^b JAWAHARLAL NEHRU TECHNOLOGICAL UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE; CD59 ANTIGEN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; INTERLEUKIN 17; LIPID; LIPOXIN; MYELOID DIFFERENTIATION FACTOR 88; POLYUNSATURATED FATTY ACID; PROSTAGLANDIN E2; TOLL LIKE RECEPTOR 4;

ARTICLE; CRITICAL ILLNESS; CYTOKINE PRODUCTION; ENVIRONMENTAL STRESS; GENE MUTATION; GENE SEQUENCE; HUMAN; IMMUNE RESPONSE; INFLAMMATION; LEUKOCYTE ACTIVATION; NECROTIZING ENTEROCOLITIS; PROTEIN EXPRESSION; SEPSIS; WOUND HEALING;

HUMANS; INFLAMMATION MEDIATORS; LIPIDS; MODELS, THEORETICAL; SEPSIS; TOLL-LIKE RECEPTORS;

EID: 84874522562     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2012.12.007     Document Type: Article

References (37)

1. Angus D.C., Linde-Zwirble W.T., Lidicker J., Clermont G., Carcillo J., Pinsky M.R. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001, 29:1303-1310.
2. Le Gall J.R., Alberti C., Brun Buisson C. Epidemiology of infection and sepsis in intensive care unit patients. Bull Acad Natl Med 2004, 188:1115-1125.
3. Melamed A., Sorvillo F.J. The burden of sepsis-associated mortality in the United States from 1999 to 2005: an analysis of multiple-cause-of-death data. Crit Care 2009, 13:R28.
4. Das U.N. Can sepsis and other critical illnesses be predicted and prognosticated?. Adv Sepsis 2006, 5:52-59.
5. Hotchkiss R.S., Karl I.E. The pathophysiology and treatment of sepsis. N Engl J Med 2003, 348:138-150.
6. Kinasewitz G.T., Yan B.S., Basson B., Comp P., Russell J.A., Cariou A., et al. For the PROWESS Sepsis Study Group. Universal changes in biomarkers of coagulation and inflammation occur in patients with severe sepsis, regardless of causative micro-organism. Crit. Care 2004, 8:R82-R90.
7. Tracey K.J., Beutler B., Lowry S.F., Merryweather J., Wolpe S., Milsark I.W., et al. Shock and tissue injury induced by recombinant human cachectin. Science 1986, 234:470-474.
8. Tracey K.J., Fong Y., Hesse D.G., Manogue K.R., Lee A.T., Kuo G.C., et al. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 1987, 330:662-664.
9. Karlsson S., Pettilä V., Tenhunen J., Laru-Sompa R., Hynninen M., Ruokonen E. HMGB1 as a predictor of organ dysfunction and outcome in patients with severe sepsis. Intensive Care Med 2008, 34:1046-1053.
10. Yang H., Ochani M., Li J., Qiang X., Tanovic M., Harris H.E., et al. Reversing established sepsis with antagonists of endogenous high mobility group box-1. Proc Natl Acad Sci USA 2004, 101:296-301.
11. Sunden-Cullberg J., Norrby-Teglund A., Rouhiainen A., Rauvala H., Herman G., Tracey K.J., et al. Persistent elevation of high mobility group box-1 protein (HMGB1) in patients with severe sepsis and septic shock. Crit Care Med 2005, 33:564-573.
12. Hagberg L., Briles D.E., Eden C.S. Evidence for separate genetic defects in C3H/HeJ and C3HeB/FeJ mice that affect susceptibility to gram-negative infections. J Immunol 1985, 134:4118-4122.
13. Felmet K.A., Hall M.W., Clark R.S., Jaffe R., Carcillo J.A. Prolonged lymphopenia, lymphoid depletion, and hypoprolactinemia in children with nosocomial sepsis and multiple organ failure. J Immunol 2005, 174:3765-3772.
14. Arbour N.C., Lorenz E., Schutte B.C., Zabner J., Kline J.N., Jones M., et al. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet 2000, 25:187-191.
15. Das U.N. Critical advances in septicemia and septic shock. Crit Care 2000, 4:290-294.
16. Schwartz D.A. The role of TLR4 in endotoxin responsiveness in humans. J Endotoxin Res 2001, 7:389-393.
17. Murthy K.G., Deb A., Goonesekera S., Szabó C., Salzman A.L. Identification of conserved domains in salmonella muenchen flagellin that are essential for its ability to activate TLR5 and to induce an inflammatory response in vitro. J Biol Chem 2004, 279:5667-5675.
18. Ryan K.A., Smith M.F., Sanders M.K., Ernst P.B. Reactive oxygen and nitrogen species differentially regulate Toll-like receptor 4-mediated activation of NF-kappa B and interleukin-8 expression. Infect Immun 2004, 72:2123-2130.
19. Shishido T., Nozaki N., Takahashi H., Arimoto T., Niizeki T., Koyama Y., et al. Central role of endogenous toll-like receptor-2 activation in regulating inflammation, reactive oxygen species production, and subsequent neointimal formation after vascular injury. Biochem Biophys Res Commun 2006, 345:1446-1453.
20. Norris P.C., Reichart D., Dumlao D.S., Glass C.K., Dennis E.A. Specificity of eicosanoid production depends on the TLR-four-stimulated macrophage phenotype. J Leukoc Biol 2011, 90:563-574.
21. Lefebvre J.S., Marleau S., Milot V., Lévesque T., Picard S., Flamand N., et al. Toll-like receptor ligands induce polymorphonuclear leukocyte migration: key roles for leukotriene B4 and platelet-activating factor. FASEB J 2010, 24:637-647.
22. Ruipérez V., Astudillo A.M., Balboa M.A., Balsinde J. Coordinate regulation ofTLR-mediated arachidonic acid mobilization in macrophages by group IVA and group V phospholipase A2s. J Immunol 2009, 182:3877-3883.
23. Font-Nieves M., Sans-Fons M.G., Gorina R., Bonfill-Teixidor E., Salas-Pérdomo A., Márquez-Kisinousky L., et al. Induction of COX-2 enzyme and down-regulation of COX-1 expression by lipopolysaccharide (LPS) control prostaglandin E2 production in astrocytes. J Biol Chem 2012, 287:6454-6468.
24. Gorina R., Font-Nieves M., Márquez-Kisinousky L., Santalucia T., Planas A.M. Astrocyte TLR4 activation induces a proinflammatory environment through the interplay between MyD88-dependent NFκB signaling, MAPK, and Jak1/Stat1 pathways. Glia 2011, 59:242-255.
25. Lu J., Jilling T., Li D., Caplan M.S. Polyunsaturated fatty acid supplementation alters proinflammatory gene expression and reduces the incidence of necrotizing enterocolitis in a neonatal rat model. Pediatr Res 2007, 61:427-432.
26. Caplan M.S., Russell T., Xiao Y., Amer M., Kaup S., Jilling T. Effect of polyunsaturated fatty acid (PUFA) supplementation on intestinal inflammation and necrotizing enterocolitis (NEC) in a neonatal rat model. Pediatr Res 2001, 49:647-652.
27. 1 mitigate acute kidney injury. J Immunol 2006, 177:5902-5911.
28. 1. J Immunol 2009, 182:3223-3232.
29. 2 is a potent regulator of leukocytes and controls microbial sepsis. Nature 2009, 461:1287-1292.
30. Bitto A., Minutoli L., David A., Irrera N., Rinaldi M., Venuti F.S., et al. Flavocoxid, a dual inhibitor of COX-2 and 5-LOX of natural origin, attenuates the inflammatory response and protects mice from sepsis. Crit Care 2012, 16:R32.
31. 4 analog attenuates lipopolysaccharide induced acute lung injury in mice. the role of heme oxygenase-1. Anesth Analg 2007, 104:369-377.
32. 4 increases survival by decreasing systemic inflammation and bacterial load in sepsis. Shock 2011, 36:410-416.
33. Norling L.V., Spite M., Yang R., Flower R.J., Perretti M., Serhan C.N. Cutting edge: humanized nano-proresolving medicines mimic inflammation-resolution and enhance wound healing. J Immunol 2011, 186:5543-5547.
34. Das U.N. Molecular Basis of Health and Disease 2011, Springer, New York.
35. Bazan N.G. The onset of brain injury and neurodegeneration triggers the synthesis of docosanoid neuroprotective signaling. Cell Mol Neurobiol 2006, 26:901-913.
36. Das U.N. Influence of polyunsaturated fatty acids and their metabolites on stem cell biology. Nutrition 2011, 27:21-25.
37. Das U.N. Essential fatty acids and their metabolites as modulators of stem cell biology with reference to inflammation, cancer, and metastasis. Cancer Metastasis Rev 2011, 30:311-324.